2022 AAN Annual Report

2022

ANNUAL REPORT

AT LAST! OUR GREAT NEURO REUNION

Dear AAN Member,

With the severity of the COVID-19 pandemic dramatically lessened in 2022, we were overjoyed to return to face-to-face meetings and conferences with friends and colleagues. True, there may have been more fist or elbow bumps than handshakes or high fives but being among our peers again for the first time since early 2020 was marvelously energizing!

The excitement was palpable at the Annual Meeting in Seattle with its Great Neuro Reunion theme. For those who were unable to attend, our Virtual Annual Meeting provided choice education and science along with some online networking opportunities.

The Summer Conference had a new focus on Autoimmune Neurology and Neurology Year in Review and attendance in San Francisco exceeded our goals. The Fall Conference in Las Vegas also performed well. Neurology on the Hill had robust participation as members visited congressional offices for the first time since 2020 and advocated for our patients and profession.

The AAN also held two important summits in 2022. In December, our third gathering of neurology academic department chairs and business administrators was rechristened the late Ralph L. Sacco Neurology Chair Summit in honor of our remarkable president who spearheaded the effort to draw academic neurologists together for the first summit in 2018 as well as other initiatives for academic neurology. The event, co-sponsored by the American Neurological Association, the Association of University Professors of Neurology, and the AAN, focused on topics such as recruiting and retaining a workforce in today’s environment, providing care for a diverse set of patients, and success stories of navigating clinical, educational, and research challenges in times of financial uncertainty.

We also launched one of the most ambitious undertakings in the history of the AAN: the Brain Health Summit. The event was accompanied by a resolution in the US Congress designating September 15, 2022, as “National Brain Health Day,” in tandem with the inaugural Brain Health Summit in Washington, DC, held on the same day. The summit brought together more than 100 leading experts, key public and private sector stakeholders, and policy makers in the United States to shape the future of care, discuss brain health over the lifespan, and outline research, education, and advocacy needs. An action plan outlining the AAN’s strategy, objectives, and tactics will become the road map for incorporating brain health into neurologic practice and developing an integrated alliance with brain health care providers in other fields.

We also were pleased to see so many friends from our international membership who attended the Annual Meeting. At the European Academy of Neurology meeting in Austria, we met with leaders from several countries and discussed brain health and other topics of mutual concern. Dr. Avitzur spoke at the 18th Asian Oceanian Congress of Neurology and 29th Annual Conference of the Indian Academy of Neurology in New Delhi (India comprises the second largest number of international members at the AAN). President Elect Carlayne E. Jackson, MD, FAAN, had the honor of speaking to the Mexican Academy of Neurology’s annual meeting. The AAN also reached out to members in war-torn Ukraine to assist neurologists who too often were on the front lines and struggling to continue treating their patients.

The Great Neuro Reunion also extended to our headquarters in Minneapolis and our new Washington, DC, office, where staff at last had the chance to meet coworkers hired during the pandemic who they’d only seen in Zoom meetings. The lobby of the Minneapolis building now greets staff and visitors with a unique display of medical tools and textbooks used by the founders of the AAN.

Even as we look back in this report on our many successes in 2022, we also look forward with great excitement to 2023 and celebrating the 75th anniversary of the founding of our beloved Academy. As Shakespeare might say, our past is also our prologue, and we can confidently report that the AAN has never been in a better position to support our 40,000 members in the future.

Orly Avitzur, MD, MBA, FAAN AAN President

@OrlyA

Mary E. Post, MBA, CAE AAN Chief Executive Officer MPost@aan.com

MEMBERSHIP

WORLD’S LARGEST PROFESSIONAL ASSOCIATION OF NEUROLOGISTS

14,500 US NEUROLOGISTS

9,500 INTERNATIONAL MEMBERS

30,500 US MEMBERS

40,000 TOTAL MEMBERS

140 COUNTRIES REPRESENTED

49% NEUROLOGIST/PHYSICIAN

18% JUNIOR/INTERN

17% STUDENT

7% SENIOR/HONORARY

2% RESEARCHER

6% ADVANCED PRACTICE PROVIDER

1% BUSINESS ADMINISTRATOR

REMARKABLE GROWTH: BY THE NUMBERS

Membership continued to grow in 2022; final membership numbers reflect a total AAN membership growth of approximately three percent. We have had nearly 95 percent retention of US dues-paying neurologists, and the number of US neurologist and APP members held steady. In addition, we saw growth in Researcher members for the first time in three years. We also had another record year for academic membership in terms of recruitment and retention of Junior members. Growth of International members means nearly one in four members is now international.

3% GROWTH IN MEMBERSHIP MEMBERSHIP

6,800*

MEMBER VOLUNTEERS

200 STAFF

95%** RETENTION

*May reflect members with multiple volunteer positions.

**Reflects retention of US neurologist members.

92% OF CURRENT US MARKET SHARE OF NEUROLOGISTS

1,900+ APP MEMBERS

WELLNESS

The Wellness Subcommittee made a successful return to in-person programming at the Annual Meeting at the Live Well Experiential Learning Area. Sessions included Bollywood Dance, Magic & Medicine, and intimate fireside chats on wellness topics.

HEALTH CARE EQUITY SYMPOSIUM

The first in-person half-day symposium occurred at the Annual Meeting.

HEALTH CARE EQUITY PROGRAM

This program kicked off in person at the Annual Meeting with 10 cohort members. It includes a year-round curriculum and chance to develop a project at their own institution to help address health care disparity. They have opportunities to continue to engage with the other cohort members and AAN leaders while continuing to strengthen their knowledge around health care disparities.

SECTIONS AND SYNAPSE

SynapseSM Member Communities continued to grow with more than 27,000 members participating in one or more of the over 60 online communities. The Synapse mobile app enhances member engagement.

ONLINE COMMUNITIES OVER 60 MEMBERS PARTICIPATE IN 27K

CAREER CENTER

Online virtual career fairs were held in January, April, July, and October. A total of 300+ interview sessions were completed. A pilot program for a new online round-robin recruitment event, similar to speed dating, was launched, and refinements will be made in 2023 based on job seeker and employer feedback. More than 200 members received free CV reviews in 2022, helping boost public, searchable CVs available in the Neurology Career Center database. The database surpassed 1,000 CVs, a new record, and is an important tool to help job seekers and employers connect.

INCLUSION, DIVERSITY, EQUITY, ANTI-RACISM, AND SOCIAL JUSTICE (IDEAS)

Awards and grants were offered, including a Clinical Research and Training Scholarship in Neurodisparities, one IDEAS Changemaker Award, two AAN IDEAS Innovator Grants, two AAN IDEAS Project Grants, and the Health Care Equity Research Award. There was an increase in IDEAS-related programming at the Annual Meeting in Seattle.

IDEAS review was incorporated in publications of all manuscripts and abstracts:

• Continuum® authors were directed to add sections on health disparities in their articles, as applicable. Staff and editors carefully review all content for inclusive and unbiased language.

• Neurology Today® and Brain & Life® each have an EDI associate editor who reviews and advises on inclusive language in stories.

• Neurology® journal achieved gender equity on all five journal Editorial Boards.

The 2022 AAN Board of Directors membership reflects a 22 percent increase in racial diversity compared to the 2017 Board of Directors, while gender and practice setting representation have remained similar.

EDUCATION

ONLINE LEARNING

NeuroPanels, free case-based webinar series with top-notch experts on each topic, was successfully piloted and will continue in 2023. NeuroSAE transformed its format from semiannual release of 100 questions to monthly release of 25 questions to meet members’ microlearning needs. The success of NeuroBytes-Medical Student pilot resulted in regular releases.

MONTHLY QUESTIONS

CONTINUING MEDICAL EDUCATION

The AAN continued work on the AAN Education Vision, providing education tools and resources that are easy to find, easy to use, and specific to each member. The Academy started its reaccreditation cycle with the Accreditation Council for Continuing Medical Education.

ACADEMIC

The 2022 Academic Neurology Department Chair and Business Administrator Summit—renamed the Ralph L. Sacco Neurology Chair Summit for the late AAN president who launched the event— was held in December after having been canceled for two years due to COVID-19.

The new Academic Learner Engagement Center available at the Annual Meeting curated academic offerings created by academicians for academicians. Two new Academic Diversity Officer Grants and one Award were given. These grants and award are specific to the AAN’s Academic Neurology Initiative.

3,420

ANNUAL MEETING ON DEMAND UNIQUE ENROLLMENTS

19,419

NEUROBYTES VIEWS

47 NEUROBYTES VIDEOS RELEASED

100 VIDEOS IN NEUROBYTES LIBRARY

1,865 ANNUAL MEETING ON DEMAND CME HOURS

x1,000

29,775 ANNUAL MEETING ON DEMAND COURSE VIEWS

5,309

UNIQUE NEUROBYTES PARTICIPANTS

54% ALUMNI REACH FAAN STATUS

LEADERSHIP DEVELOPMENT

The relaunch of Leadership University occurred in person at both the Annual Meeting in Seattle and the Fall Conference in Las Vegas. In 2022, 54 percent of alumni had reached FAAN status, continuing the rise in engagement with the alumni of the Leadership Programs and the AAN. The second long-term follow-up assessment was disseminated for comparison to the benchmark set in 2020 to continue to follow alumni and their progress in reaching their leadership potential.

EDUCATION AWARDS AND SCHOLARSHIPS

A variety of awards and scholarships were offered for trainees and educators, with 10 available for trainees and nine for educators. Visiting Scholarships were brought back as the pandemic eased.

SCHOLARSHIP AND AWARDS

10 TRAINEE 9 EDUCATOR

TRAINEES

In consideration of the pandemic and lessons learned from the past two years of virtual interviews, the AAN Consensus Statement on 2022–2023 Application Cycle advised neurology and child neurology residency/fellowship programs to commit to virtual interviews for all applicants in place of in-person interviews for the 2022–2023 application cycle. The Student Interest Group in Neurology (SIGN) launched the pilot blog SIGNposts to encourage medical students to write about and disseminate their work to guide fellow students through this formative period as they transition from medical school to residency.

COMMITTING TO VIRTUAL INTERVIEWS

RESEARCH

3,010

ABSTRACTS SUBMITTED

PUBLICATIONS

The Neurology ® Education journal launched. This onlineonly, peer-reviewed journal publishes original research articles, reviews, and editorials on evidence-based teaching methods and curriculum innovations.

The Video Journal Club premiered on the Neurology ® website. This site features experts discussing Neurology ® journal articles and hot topics in the field of neurology.

A new manuscript tracking system for the Neurology journals with an intuitive, efficient submission system enabling faster review of manuscripts was launched.

AWARDS

All AAN awardees were recognized during the Annual Meeting in the Awards Theater. The theater featured a selfie spot, recognition panels, and a presentation stage, along with recognition opportunities throughout the week.

ABSTRACTS

The 2022 Annual Meeting attracted 3,010 abstract submissions and just over 2,200 were presented both in person and virtually.

The new 2022 Summer Conference focused on Autoimmune Neurology received 204 abstract submissions, with 183 accepted and presented as data blitz and posters.

183 ACCEPTED ABSTRACTS

GRANTS

3 1 26 EDUCATION $10,OOO EACH MEDICAL FELLOWSHIP $65,000

RESEARCH PROGRAMS AND GRANTS

The 2022 Research Program received 154 applications for the 26 awards offered, which includes the Career Development Awards and the Clinical Research Training Scholarships. Three Education Research Grants ($10,000) and one Medical Research Training Fellowship ($65,000) were awarded after not being offered for a few years. Other awards included three ($3,000) Resident Research Scholarships and twenty ($3,000) Medical Student Research Scholarships.

PRACTICE

PRACTICE MANAGEMENT

QUALITY MEASURES

The AAN published seizure frequency process and outcome quality measures. The Geriatric Quality Measurement Work Group joined six other standing groups. IDEAS innovations included requesting DEI input on drafts (stroke outpatient), objective assessment of author panel diversity, and template changes to capture DEI considerations.

Business administrators were engaged with personalized membership onboarding and small networking cohorts. Prior authorization outreach was conducted with payers and development of resources. Web pages devoted to Managing Staffing Challenges and Neurology Practice Efficiencies were created to help members navigate challenging times.

Two new telehealth resources were created—a guide to telehealth visits for patients with a neuromuscular disorder, and one for vestibular disorder.

70%

VALUE-BASED CARE

Case studies were developed to help membership better understand different care delivery models. A bite-sized webinar series on population health fundamentals was produced. Resources were provided to members regarding three new MIPS Value Pathways available for neurology as part of the CMS Quality Payment Program.

NEUROLOGISTS ARE MOTIVATED TO INCREASE TELEHEALTH USE

GUIDELINES

“Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis—Practice Advisory” and “Aducanumab Use in Symptomatic Alzheimer’s Disease—Evidence in Focus” were published. Work started on the management of functional seizures guideline and protocol was posted for public comment.

Expeditious evaluation is reasonable as the highest risk of recurrent stroke is soon after the incident event.

Level Recommendation Level B Clinicians should utilize diagnostic modalities to diagnose s-ICAS and distinguish from other intracranial vasculopathies if the results would be expected to change management or provide important prognostic information.

Antithrombotic Medication Therapy

Recommendations 2, 3, and 4 Rationale The Warfarin-Aspirin Symptomatic Intracranial Disease trial (WASID) showed that in patients with s-ICAS, aspirin 650 mg twice daily was safer and as effective as warfarin for preventing the combined endpoint of stroke, intracerebral hemorrhage, and vascular death. While the optimal aspirin dose for s-ICAS has not been determined, patients in the medical arm of the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis trial (SAMMPRIS) were treated with aspirin alone 325 mg/day after the first 90 days. Other antiplatelet agents used for stroke prevention (e.g., ticagrelor or combination dipyridamole and aspirin) and other doses of aspirin have not been specifically studied in s-ICAS. The safety and efficacy of novel oral anticoagulants for prevention of stroke in s-ICAS are

Evidence in Focus: Aducanumab Use

in Q&AAlzheimerSymptomaticDisease

for Patients and Families

lower primary endpoint rate compared with similar patients from

WASID treated with aspirin alone at 1 month (5.8% vs 10.5%) and 6 months (8.9% vs 17.9%).13,14 This analysis of WASID patients who met SAMMPRIS entry criteria was adjusted for confounding factors and still showed almost double the risk of stroke in the WASID patients, despite the higher burden of poor prognostic features in the SAMMPRIS patients. The optimal duration of combined clopidogrel and aspirin in s-ICAS has not been tested in randomized controlled trials (RCTs) and remains unknown, but the high rate of stroke beyond the first few months on aspirin alone in the medical arm of SAMMPRIS suggests further study is needed to determine extending clopidogrel use beyond 3 months is warranted.

Trials of cilostazol combined with other antiplatelet agents for stroke prevention in s-ICAS have had mixed results. The Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis (TOSS) and TOSS-2 trials found cilostazol plus aspirin was not better for stroke prevention than aspirin alone or clopidogrel plus aspirin. However, the Cilostazol-aspirin Therapy Against Recurrent Stroke with Intracranial Artery Stenosis

Aducanumab is the first drug approved by the Food and Drug Administration to treat some of the underlying brain changes associated with Alzheimer disease. Studies have shown that this drug helps remove amyloid-β plaques from the brain, one substance thought to play a role in the development of Alzheimer disease. However, we still do not know what effect aducanumab has on symptoms related to Alzheimer disease. One study showed that patients receiving this medication had slightly slower rates of memory decline than patients receiving a placebo while another study failed to show such an effect. Aducanumab is intended for patients with relatively mild memory problems—not patients with moderateto-severe problems. Side effects are common with aducanumab use, and patients taking this drug will need to be monitored often for side effects. Aducanumab is a new drug, so what to expect with long-term treatment is unknown. If your clinician suggests that you consider using aducanumab, the following questions and answers may help guide your discussions. Howdoesaducanumabwork?  Aducanumab removes amyloid-β plaques from the brain. Accumulation of amyloid-β is thought to play

IDEAS innovations included requesting DEI input on drafts, objective assessment of author panel diversity, template changes to capture DEI considerations, and focus on inclusive language (initiated in the epilepsy and pregnancy public comment pilot and to roll out to other projects).

a role in the development of Alzheimer disease and memory problems (mild cognitive impairment or dementia due to Alzheimer disease. Whoshoulduseaducanumab?  The Food and Drug Administration approved aducanumab only for people with brain changes due to Alzheimer disease who are at the mild cognitive impairment or initial stages of dementia. Mild cognitive impairment is when a person’s memory is worse, but they can still do day-to-day activities on their own. Dementia is when a person’s memory and thinking are more severely affected, and the person needs help with day-to-day activities. Dementia is often thought of as occurring in older adults; however, it can occur in younger adults as well (young-onset dementia  The Food and Drug Administration did not specify who should not receive aducanumab. However, studies of aducanumab did not include:

• People with dementia that is not related to Alzheimer disease

• People who take blood thinners or have a history of bleeding disorders, brain bleeding, or stroke Also, traditionally underrepresented minority groups were not well represented in the studies.

Tolearnmore,visit

AXON REGISTRY

Two reports were developed, and three submissions made to Neurology related to Axon Registry® data. The Parkinson’s disease analytics report was developed for internal committee distribution to promote and highlight the potential of the registry. The first research proposal in the Axon Registry research pilot study was completed on optic neuritis. The transition from FIGmd to Verana Health continued.

$1.5 TRILLION

ADVOCACY

MEDICARE

EXTENDED TELEHEALTH FROM COVID-19

ADDITIONAL ADVOCACY SUCCESSES

Congress enacted laws that aligned with the AAN's top advocacy priorities, including:

• $1.5 trillion in spending for fiscal year 2022 that funded critical federal medical research programs at historic levels, including $45 billion to the National Institutes of Health, an increase of more than $2 billion.

• Extension of several COVID-19-related telehealth flexibilities through the end of 2024 through passage of the Inflation Reduction Act.

• The Inflation Reduction Act addressed the high costs of prescription drugs (among other issues), which the AAN had tirelessly championed through countless meetings with individual members of Congress, several Neurology on the Hill events, numerous comment letters and coalition messages, and much more.

REDUCED MEDICARE CUTS

Congress eliminated three-quarters of the scheduled 8.5 percent Medicare reimbursement reduction, resulting in a net two-percent reduction in payments for 2023. While the AAN recognizes that any cuts to Medicare reimbursement continue to threaten practices and patient access to care, this lesser reduction remains a hard-fought victory for neurology. We will not let up on the pressure in 2023 with the new Congress to ensure that our practitioners receive appropriate reimbursement for their care and expertise.

ADVOCACY FOR ALZHEIMER’S DISEASE TREATMENT

The Centers for Medicare & Medicaid Services (CMS) released its final National Coverage Determination (NCD) for monoclonal antibodies (mAbs) directed against amyloid for the treatment of Alzheimer’s disease (AD). The AAN engaged with regulators and other stakeholders on issues relating to AD mAbs since prior to the FDA’s approval of aducanumab in June 2021. The final NCD contained many of the AAN’s critical priorities, and, reflecting the strength of the Academy’s reputation and advocacy, the AAN was referenced extensively throughout the final NCD in sections regarding appropriate site requirements, care team design, and more.

ACTION ALERTS

More than 2,000 members responded to Action Alerts sent by the Academy on topics such as Medicare reimbursement cuts. Their emails to their lawmakers in Congress helped amplify the voice of neurologists and supported efforts by AAN leadership and staff.

NEUROLOGY ON THE HILL

The 20th Annual Neurology on the Hill was held May 23–24, 2022, in Washington, DC. Nearly 160 AAN members from 39 states met with their legislators to advocate for legislation to: provide stability for telehealth, address overly burdensome utilization management, and enact policies to address the neurology workforce.

160

During the event, the 2nd Annual Janice F. Wiesman Congressional Leadership in Neurology Award was presented to Rep. Brad Wenstrup (R-OH-2). AAN MEMBER ADVOCATES

EVENTS

BRAIN HEALTH

BRAIN HEALTH SUMMIT

The inaugural AAN Brain Health Summit was held on September 15 in Washington, DC, convening together leading experts, key public and private sector stakeholders, and policy makers in the United States to shape the future of care, discuss brain health over the lifespan, and outline research, education, and advocacy needs. In conjunction with the summit, the AAN worked with US Representatives Earl Blumenauer (D-OR) and Morgan Griffith (R-VA) to introduce a resolution to designate September 15, 2022, as “National Brain Health Day.” According to the resolution, the purpose of National Brain Health Day is to increase public awareness of brain health and support efforts to study and develop better treatments to improve brain health.

SHAPING THE FUTURE OF CARE

BRAIN HEALTH OVER LIFESPAN

FIRST HYBRID EVENT

SUMMER CONFERENCE

The new Summer Conference focused on Autoimmune Neurology and Neurology Year in Review was held July 26–27 in San Francisco. The conference was the first foray into a hybrid event, with 767 total registrants in person and online. The conference was rated Good or Excellent by 99 percent of attendees.

ATTENDEES

FALL CONFERENCE

The first in-person Fall Conference since 2019 was held at Caesars Palace in Las Vegas, October 28–30, with 792 in-person or online professional registrants. Prior to the conference, two pre-conferences were offered: Advanced Practice Providers and Sports Concussion.

ATTENDEES 792

98%

EXCELLENT/GOOD SATISFACTION RATING

4,590

VIRTUAL ATTENDEES

8,344

IN-PERSON ATTENDEES

ANNUAL MEETING

For the first time since 2019, the Annual Meeting was held in person. The AAN saw 8,344 attendees in person in Seattle with an additional 4,590 attendees during the Virtual Annual Meeting offered three weeks later. The meeting was rated good or excellent by 98 percent of attendees. The AAN committed to creating a safe and healthy environment for all attendees in Seattle.

EPISODES PUBLISHED 41

Top Episodes

Brain Health for Women

Hop on a Cure for ALS – John Driskell Hopkins

Master Chef Christine Ha – Adapting to Life with NMO

Restless Legs Syndrome, TBI, & Brain Surgery

BJ Miller – Guiding Chris Hemsworth Through a New Outlook on Life

Listener Favorite: Lauren Miller Rogen on Facing a

Parent’s Early-Onset Alzheimer’s Diagnosis

BRAIN & LIFE PODCAST

The Brain & Life podcast was launched, inspired by the AAN’s highly successful Brain & Life® patient and caregiver magazine. The weekly podcast featured people whose lives are affected by brain disease, neurology experts, and celebrity advocates including actor and comedian George Lopez, actor Marilu Henner, and musician Peter Frampton. In 2022, 41 episodes were published.

ADDITIONAL ACCOMPLISHMENTS

AAN UKRAINE CRISIS RESPONSE WORK GROUP

Immediately following the Russian invasion of Ukraine, the AAN heard from members in the region who needed help as they struggled to provide their neurology patients with continued care. The AAN Ukraine Crisis Response Work Group was created to assist neurologists in the region. The AAN provided free access to AAN publication content and made connections with organizations who provided donated items to neurology practices in need.

INDUSTRY

The AAN continued to partner with Industry Roundtable members, receiving a record $1.69 million in support from 41 companies. Industry partners were excited to get back on-site for the 2022 Annual Meeting, which included more than 130 exhibitors, 23 Industry Therapeutic Updates, numerous sponsorships, and support for CME programs. More than $550,000 was raised for the Leadership Programs in 2022.

$1.69M SUPPORT FROM 41 COMPANIES

SUPPORT FROM 41 COMPANIES

$550,000+ RAISED FOR LEADERSHIP PROGRAM

87 CENTS OF EVERY DOLLAR

DIRECTLY APPLIED TO MEMBER BENEFITS

$68.4M 2022 REVENUE

$64.2M 2022 EXPENSES

38% ROYALTIES & PUBLICATIONS

16% MEMBERSHIP DUES

19% CONFERENCE & EDUCATION

19% GRANTS & GIFTS

8% OTHER

36% EDUCATION

13% GENERAL & ADMINISTRATIVE

14% MEMBERSHIP

13% GRANTS & AWARDS

9% PUBLICATIONS

9% ADVOCACY

6% CLINICAL PRACTICE

VISION

TO BE INDISPENSABLE TO OUR MEMBERS

MISSION

TO PROMOTE THE HIGHEST QUALITY PATIENT-CENTERED NEUROLOGIC CARE AND ENHANCE MEMBER CAREER SATISFACTION

2022 AAN GOALS

Our 2022 goals describe how the leaders, members, and staff of the Academy will accomplish our mission and achieve our vision. These goals envision a preferred future to which we aspire for the American Academy of Neurology – a future in which we achieve our vision to be indispensable to all our members.

DEMONSTRATE AND ASSERT THE VALUE OF NEUROLOGY and brain health to policymakers, patients, the public, and other major stakeholders

GROW THE NEUROLOGY WORKFORCE and innovate care delivery to meet the future needs for patient care

DEMONSTRATE AND COMMUNICATE OUR COMMITMENT to be a fully inclusive, diverse, and anti-racist organization that promotes neurologic health equity and actively works to recruit and support a diverse membership

ENSURE THE HEALTH OF THE GLOBAL NEUROLOGY COMMUNITY and enhance member satisfaction, well-being and resiliency, and engagement

ADVOCATE AND SUPPORT the financial well-being, continuing viability, and innovation of the practice of neurology

EXPAND AND SUPPORT neuroscience research

CREATE NOVEL WAYS TO EDUCATE AND ASSIST MEMBERS in providing high-value, team-based, patient-centered, clinical care

AAN BOARD OF DIRECTORS

OFFICERS

President: Orly Avitzur, MD, MBA, FAAN

President Elect: Carlayne E. Jackson, MD, FAAN

Vice President: Janis M. Miyasaki, MD, FAAN

Secretary: Sarah M. Benish, MD, FAAN

Treasurer: Charles C. Flippen, II, MD, FAAN

Immediate Past President: James C. Stevens, MD, FAAN

DIRECTORS

Wayne E. Anderson, DO, FAHS, FAAN

Brenda Banwell, MD, FAAN

Charlene E. Gamaldo, MD, FAAN, FAASM

James N. Goldenberg, MD, FAAN

Larry B. Goldstein, MD, FAHA, FAAN

Lily Jung Henson, MD, MMM, FAAN

Shannon M. Kilgore, MD, FAAN

Brett M. Kissela, MD, MS, FAHA, FAAN

Bruce I. Ovbiagele, MD, MSc, MAS, MBA, FAAN

EX OFFICIO (VOTING)

Bruce H. Cohen, MD, FAAN

Brad C. Klein, MD, MBA, FAAN

Maisha T. Robinson, MD, MSHPM, FAAN

José G. Merino, MD, MPhil, FAAN, Editor-in-Chief, Neurology®

EX OFFICIO (NON-VOTING)

Mary E. Post, MBA, CAE

AAN INSTITUTE BOARD OF DIRECTORS

OFFICERS

Chair: Orly Avitzur, MD, MBA, FAAN

Chair Elect: Carlayne E. Jackson, MD, FAAN

Vice Chair: Janis M. Miyasaki, MD, FAAN

Secretary-Treasurer: Jonathan Hosey, MD, FAAN

DIRECTORS

Wayne E. Anderson, DO, FAHS, FAAN

Brenda Banwell, MD, FAAN

Charlene E. Gamaldo, MD, FAAN, FAASM

James N. Goldenberg, MD, FAAN

Larry B. Goldstein, MD, FAHA, FAAN

Lily Jung Henson, MD, MMM, FAAN

Shannon M. Kilgore, MD, FAAN

Brett M. Kissela, MD, MS, FAHA, FAAN

Bruce I. Ovbiagele, MD, MSc, MAS, MBA, FAAN

EX OFFICIO (VOTING)

Lyell K. Jones, MD, FAAN

José G. Merino, MD, MPhil, FAAN, Editor-in-Chief, Neurology®

Natalia S. Rost, MD, MPH, FAHA, FAAN

Joseph I. Sirven, MD, FAAN

Charles C. Flippen II, MD, FAAN

Sarah M. Benish, MD, FAAN

James C. Stevens, MD, FAAN

EX OFFICIO (NON-VOTING)

Mary E. Post, MBA, CAE

COMMITTEE CHAIRS

AAN DELEGATION TO THE AMA

Mark Milstein, MD, FAAN

AANI EXECUTIVE COMMITTEE

Orly Avitzur, MD, MBA, FAAN

ACADEMIC NEUROLOGY COMMITTEE

David M. Greer, MD, FAAN

ADVOCACY COMMITTEE

Bruce H. Cohen, MD, FAAN

BOARD PLANNING COMMITTEE

James N. Goldenberg, MD, FAAN

BRAINPAC EXECUTIVE COMMITTEE

Glen R. Finney, MD, FAAN

COMMITTEE ON PUBLIC ENGAGEMENT

David A. Evans, MBA

Natalia S. Rost, MD, MPH, FAHA, FAAN

COMPENSATION COMMITTEE

Jonathan P. Hosey, MD, FAAN

EDUCATION COMMITTEE

Joseph I. Sirven, MD, FAAN

ETHICS, LAW AND HUMANITIES COMMITTEE

Leon G. Epstein, MD, FAAN

FAIR HEARING PANEL COMMITTEE

Lynne P. Taylor, MD, FAAN

GRIEVANCE COMMITTEE

Peter B. Kang, MD, FAAN

HISTORY AND ARCHIVES COMMITTEE

Douglas J. Lanska, MD, FAAN JOINT AUDIT COMMITTEE

Sheri L. Farber, CPA, MBA

JOINT INVESTMENT COMMITTEE

James C. Stevens, MD, FAAN

JOURNAL ARBITRATION COMMITTEE

Lisa M. DeAngelis, MD, FAAN LEADERSHIP DEVELOPMENT COMMITTEE

Terrence L. Cascino, MD, FAAN

MEDICAL ECONOMICS AND PRACTICE COMMITTEE

Brad C. Klein, MD, MBA, FAAN

MEETING MANAGEMENT COMMITTEE

Ann H. Tilton, MD, FAAN MEMBER ENGAGEMENT COMMITTEE

Maisha T. Robinson, MD, MSHPM, FAAN PUBLICATIONS COMMITTEE

José G. Merino, MD, MPhil, FAAN

QUALITY COMMITTEE

Lyell K. Jones, MD, FAAN SCIENCE COMMITTEE

Natalia S. Rost, MD, MPH, FAHA, FAAN